Haleon PLC Sponsored ADR $HLN Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. decreased its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 16.4% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 540,052 shares of the company’s stock after selling 106,188 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Haleon were worth $4,844,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of HLN. JTC Employer Solutions Trustee Ltd lifted its stake in Haleon by 120.7% during the 3rd quarter. JTC Employer Solutions Trustee Ltd now owns 712,229 shares of the company’s stock valued at $6,392,000 after acquiring an additional 389,467 shares during the period. Archford Capital Strategies LLC acquired a new stake in shares of Haleon in the third quarter worth $2,149,000. Arlington Partners LLC raised its holdings in shares of Haleon by 128.0% during the third quarter. Arlington Partners LLC now owns 508,886 shares of the company’s stock worth $4,565,000 after purchasing an additional 285,692 shares during the last quarter. New York State Common Retirement Fund purchased a new position in shares of Haleon during the second quarter worth $3,964,000. Finally, Acadian Asset Management LLC lifted its position in Haleon by 3,031.5% during the second quarter. Acadian Asset Management LLC now owns 5,384,661 shares of the company’s stock valued at $55,813,000 after purchasing an additional 5,212,711 shares during the period. 6.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on HLN shares. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research report on Monday, December 15th. Deutsche Bank Aktiengesellschaft cut Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Finally, HSBC raised shares of Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Trading Up 1.1%

Shares of HLN stock opened at $11.16 on Thursday. Haleon PLC Sponsored ADR has a 1-year low of $8.71 and a 1-year high of $11.42. The company has a market cap of $49.71 billion, a price-to-earnings ratio of 28.62 and a beta of 0.19. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63. The stock has a 50 day simple moving average of $10.11 and a 200-day simple moving average of $9.69.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.